New hope for boys with Muscle-Wasting disease: safer steroid shows promise
NCT ID NCT05185622
Summary
This study tested vamorolone, a new type of steroid medication, in boys with Duchenne muscular dystrophy (DMD). It aimed to see if the drug was safe and how the body processed it, while also looking for early signs of benefit. The trial included 54 boys, aged 2-4 and 7-18, who took the drug daily for 12 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alberta's Children Hospital
Calgary, Alberta, AB T3B 6A8, Canada
-
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3N1, Canada
-
Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1, Canada
-
Montreal Childrens Hospital
Montreal, H4A 3J1, Canada
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
Conditions
Explore the condition pages connected to this study.